HEMO Stock Overview
A preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Hemogenyx Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.014 |
| 52 Week High | UK£0.071 |
| 52 Week Low | UK£0.011 |
| Beta | 3.05 |
| 1 Month Change | -8.37% |
| 3 Month Change | -23.11% |
| 1 Year Change | -6.27% |
| 3 Year Change | -25.70% |
| 5 Year Change | -43.76% |
| Change since IPO | -52.20% |
Recent News & Updates
Recent updates
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?
Aug 21
Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?
May 04We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully
Jan 06Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?
Oct 09Shareholder Returns
| HEMO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.8% | 1.4% | -0.6% |
| 1Y | -6.3% | -19.4% | 6.3% |
Return vs Industry: HEMO exceeded the UK Biotechs industry which returned -21% over the past year.
Return vs Market: HEMO underperformed the UK Market which returned 6.4% over the past year.
Price Volatility
| HEMO volatility | |
|---|---|
| HEMO Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: HEMO's share price has been volatile over the past 3 months.
Volatility Over Time: HEMO's weekly volatility has decreased from 13% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 14 | Vladislav Sandler | www.hemogenyx.com |
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Hemogenyx Pharmaceuticals Plc Fundamentals Summary
| HEMO fundamental statistics | |
|---|---|
| Market cap | UK£19.24m |
| Earnings (TTM) | -UK£6.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs HEMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HEMO income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£6.69m |
| Earnings | -UK£6.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.005 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HEMO perform over the long term?
See historical performance and comparison